| Hazard Information | Back Directory | [Uses]
Cavrotolimod is an immunostimulatory spherical nucleic acid (SNA) modified with type B CpG oligonucleotides designed to agonize TLR9 and elicit immune responses useful in oncology applications. | [References]
[1] Daniel WL, Lorch U, Mix S, Bexon AS. A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation.?Front Immunol. 2022;13:1073777. DOI:10.3389/fimmu.2022.1073777
[2] Rubatto M, Sciamarrelli N, Borriello S, et al. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer.?Front Med (Lausanne). 2023;9:959289. DOI:10.3389/fmed.2022.959289 |
|
|